Calton & Associates’s Abiomed Inc ABMD Stock Holding History

Calton & Associates’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-607	Closed	-$228K	–	318
2018 Q2	$228K	Buy	+607	New	+$220K	0.07%	247

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Calton & Associates's ABMD Position: Q3 2018 in Review

Calton & Associates sold out of Abiomed Inc (ABMD) in Q3 2018, closing a stake of 607 shares — an estimated $228K sold.

Calton & Associates first reported a position in ABMD in Q2 2018 and held it in 1 quarter. The position peaked at $228K in Q2 2018. 529 funds tracked by Wall St. Rank hold ABMD as of Q3 2018.

Calton & Associates reported no remaining Abiomed Inc position as of Q3 2018 after selling out during the quarter.
Calton & Associates sold 607 Abiomed Inc shares in Q3 2018, an estimated $228K.
Calton & Associates first reported a position in Abiomed Inc in Q2 2018 and held it in 1 quarter.
Calton & Associates's Abiomed Inc position peaked at $228K in Q2 2018.
529 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2018.

Based on Calton & Associates's 13F filing for Q3 2018, filed 24 Oct 2018.